StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Mon, 31 Aug 2026 06:54:10 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $8.00 price target on Gain Therapeutics (NASDAQ: GANX).

The analyst commented: "We remind investors that Gain Therapeutics has received FDA authorization for the company’s Investigational New Drug (IND) application for its lead candidate GT-02287 (International Non-proprietary Name rexaceract). The FDA’s decision will allow the start of Gain’s Phase 2 clinical assessment of GT-02287 in Parkinson’s disease (PD) with or without a GBA1 mutation in the U.S. Both the Phase 1a and Phase 1b studies of GT-02287 were conducted in Australia. The sites in Australia are expected to also participate in the

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Tue, 25 Aug 2026 07:00:00 -0400

BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in one-on-one meetings at the H.C. Wainwright 28^th Annual Global Investment Conference, held September 14-16 in New York City, NY.

On-demand Company Presentation

Date and Time: Friday, September 11, 2026; replay available beginning 7:00 a.m. ET

Access a replay here or visit the “Investors & Media/News & Events”

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Tue, 25 Aug 2026 07:00:00 -0400

On-demand Company Presentation

Date and Time: Friday, September 11, 2026; replay available beginning 7:00 a.m. ET

Access a replay here or visit the “Investors & Media/News & Events”

Form 10-Q Gain Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905713.html

Form 10-Q Gain Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905713.html

Form 8-K Gain Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905609.html

Form 8-K Gain Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905609.html

Gain Therapeutics, Inc. (GANX) Tops Q2 EPS by 3c

Tue, 11 Aug 2026 07:20:31 -0400

Gain Therapeutics, Inc. (NASDAQ: GANX) reported Q2 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Gain Therapeutics, Inc. (GANX) click here.

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.

“The second quarter marked an important period of execution for Gain, highlighted by FDA authorization of our IND for rexaceract, which positions us to advance into Phase 2 clinical development,” said Gene Mack, President and CEO of Gain Therapeutics. “The encouraging biomarker and clinical

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Nicaise Claude

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782270.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Nicaise Claude

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782270.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: GOLDSTEIN DOV A MD

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782275.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: GOLDSTEIN DOV A MD

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782275.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Islam Khalid

Fri, 17 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26782267.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Islam Khalid

Fri, 17 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26782267.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Riley Jeffrey Scott

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782257.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Riley Jeffrey Scott

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782257.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Melincoff Gwen A

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782262.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Melincoff Gwen A

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782262.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: HASLER HANS PETER

Fri, 17 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26782247.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: HASLER HANS PETER

Fri, 17 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26782247.html

Form 8-K Gain Therapeutics, Inc. For: Jul 16

Thu, 16 Jul 2026 07:53:00 -0400

si-local-file:///var/storage/secattach/20260716/26776800.html

Form 8-K Gain Therapeutics, Inc. For: Jul 16

Thu, 16 Jul 2026 07:53:00 -0400

si-local-file:///var/storage/secattach/20260716/26776800.html

Gain Therapeutics updates rexaceract trial data, plans Phase 2 start

Thu, 16 Jul 2026 07:00:18 -0400

Gain Therapeutics, Inc. (Nasdaq: GANX) issued a shareholder letter outlining clinical progress for its lead Parkinson's disease drug candidate, rexaceract, and announced two executive promotions, according to a company statement.

All 16 participants in the ongoing Phase 1b open-label extension study remained enrolled at Day 150. Following a review on July 6, 2026, an independent Data Monitoring Committee recommended the study continue without modification. Longer-term outcomes are expected to read out in October 2026, with interim updates at 270 days anticipated over the summer.

Among participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid, the compound produced an average 81%